TD Private Client Wealth LLC Buys 388 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

TD Private Client Wealth LLC boosted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 22.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 2,099 shares of the company’s stock after buying an additional 388 shares during the quarter. TD Private Client Wealth LLC’s holdings in Amphastar Pharmaceuticals were worth $78,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Pacer Advisors Inc. lifted its position in shares of Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock valued at $50,139,000 after buying an additional 1,347,775 shares in the last quarter. Boston Trust Walden Corp raised its stake in Amphastar Pharmaceuticals by 81.4% during the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock worth $36,347,000 after acquiring an additional 439,281 shares during the period. Boston Partners purchased a new position in Amphastar Pharmaceuticals during the fourth quarter valued at approximately $15,778,000. Wealthfront Advisers LLC bought a new position in shares of Amphastar Pharmaceuticals in the fourth quarter worth approximately $9,268,000. Finally, Hotchkis & Wiley Capital Management LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the third quarter worth $10,804,000. Institutional investors own 65.09% of the company’s stock.

Insider Buying and Selling

In other news, CFO William J. Peters sold 4,231 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Trading Down 0.2 %

Shares of AMPH opened at $28.39 on Wednesday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $25.89 and a twelve month high of $53.96. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The company’s fifty day simple moving average is $31.52 and its 200-day simple moving average is $40.24. The company has a market cap of $1.35 billion, a P/E ratio of 9.46, a P/E/G ratio of 2.19 and a beta of 0.77.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.